Department of Structural and Chemical Biology, Mount Sinai School of Medicine, Icahn Medical Institute Building, 1425 Madison Avenue, Box 1677, New York, NY 10029-6574, United States.
Life Sci. 2010 Apr 10;86(15-16):590-7. doi: 10.1016/j.lfs.2009.05.004. Epub 2009 May 22.
For years, conventional drug design at G-protein coupled receptors (GPCRs) has mainly focused on the inhibition of a single receptor at a usually well-defined ligand-binding site. The recent discovery of more and more physiologically relevant GPCR dimers/oligomers suggests that selectively targeting these complexes or designing small molecules that inhibit receptor-receptor interactions might provide new opportunities for novel drug discovery. To uncover the fundamental mechanisms and dynamics governing GPCR dimerization/oligomerization, it is crucial to understand the dynamic process of receptor-receptor association, and to identify regions that are suitable for selective drug binding. This minireview highlights current progress in the development of increasingly accurate dynamic molecular models of GPCR oligomers based on structural, biochemical, and biophysical information that has recently appeared in the literature. In view of this new information, there has never been a more exciting time for computational research into GPCRs than at present. Information-driven modern molecular models of GPCR complexes are expected to efficiently guide the rational design of GPCR oligomer-specific drugs, possibly allowing researchers to reach for the high-hanging fruits in GPCR drug discovery, i.e. more potent and selective drugs for efficient therapeutic interventions.
多年来,G 蛋白偶联受体 (GPCR) 的传统药物设计主要集中在抑制单个受体在通常定义明确的配体结合位点上。最近发现越来越多的生理相关 GPCR 二聚体/寡聚体表明,选择性靶向这些复合物或设计抑制受体-受体相互作用的小分子可能为新药发现提供新的机会。为了揭示控制 GPCR 二聚化/寡聚化的基本机制和动力学,理解受体-受体相互作用的动态过程并确定适合选择性药物结合的区域至关重要。这篇综述强调了基于最近文献中出现的结构、生化和生物物理信息,开发越来越精确的 GPCR 寡聚体动态分子模型的最新进展。鉴于这些新信息,现在是计算研究 GPCR 比以往任何时候都更令人兴奋的时刻。基于信息的现代 GPCR 复合物分子模型有望有效地指导 GPCR 寡聚体特异性药物的合理设计,这可能使研究人员能够在 GPCR 药物发现中达到高挂的果实,即更有效治疗干预的更有效和选择性药物。